Notice for belzutifan (Merck Sharp & Dohme (Australia) Pty Ltd)
Active ingredients
belzutifan
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Immediate-release tablet
Indication
For the treatment of von Hippel-Lindau (VHL) disease
Therapeutic area
Oncology